All Industries

Top Biotech Companies

3,138 Biotech companies, sorted by total funding raised.

SuperGenClosed

Pharmaceutical company dedicated to the discovery and development of novel cancer therapies.

Dublin, United States201–500Biotech
Corporate Round·$391.6M·Oct 2009
Avenzo Therapeutics

Clinical-stage oncology company developing next-generation cancer therapies, founded in 2022 and ...

San Diego, United States11–50Biotech, Healthcare
Series A·$386.0M·Nov 2024
23andMeIPO

Developing new ways to help people make sense of their genetic information

San Francisco Bay Area, United States501–1000Biotech, DNA Testing
Series B·$382.5M·Dec 2020
SaludaIPO

Neurostimulation company developing closed-loop spinal cord stimulation technology for chronic pa...

AustraliaBiotech, Healthcare
Growth Equity·$375.0M·Jan 2025
Avalyn PharmaceuticalsIPO

Biopharmaceutical company developing improved therapies for idiopathic pulmonary fibrosis (IPF), ...

Seattle, United States51–200Biotech, Healthcare
Series D·$372.5M·Jul 2025
MapLight TherapeuticsIPO

AI-powered neuroscience drug discovery platform for CNS diseases.

San Francisco, United States51–200Artificial Intelligence, Biotech
Series D·$372.5M·Jul 2025
Avalyn

Developing inhaled therapies to treat people with severe respiratory disease.

Boston, United States11–50Biotech, Healthcare
Series D·$372.5M·Jul 2025
Formation Bio

Tech-native pharma company acquiring and developing clinical-stage assets via proprietary sourcin...

New York, United States51–200Artificial Intelligence, Biotech
Series D·$372.0M·Jun 2024
Vividion TherapeuticsAcquired

Vividion Therapeutics is a Bayer-owned biopharmaceutical company using chemoproteomics-based drug...

San Diego, United States201–500Biotech, Drug Discovery
Series C·$368.0M·Feb 2021
Windward Bio

Clinical-stage drug development company improving outcomes for people with advanced immunological...

United States1–10Biotech, Healthcare
Growth Equity·$365.0M·May 2026
Pathos

Pathos is an AI-enabled biotechnology company focused on re-engineering drug development.

Chicago, United States51–200Artificial Intelligence, Biotech
Series D·$365.0M·May 2025
DELFI Diagnostics

Develops blood-based liquid biopsy tests using fragmentomics and machine learning to detect and m...

Baltimore, United States51–200Artificial Intelligence, Biotech
Venture Unknown·$364.8M·Dec 2025
Oricell Therapeutics

Clinical-stage oncology company developing novel CAR-T cell therapies for hematological malignanc...

Shanghai, China51–200Oncology, Therapeutics
Venture Unknown·$364.0M·Apr 2026
Umoja

Develops in vivo CAR T cell therapies that generate CAR T cells inside patients to treat cancer.

Seattle, United States201–500Biotech, Drug Discovery
Series C·$363.0M·Jan 2025
VO
Verastem OncologyIPO

Biopharmaceutical company developing RAS/MAPK pathway therapies for cancer patients.

Needham, United States51–200Biotech, Healthcare
Corporate Round·$360.5M·Nov 2025
Ventus Therapeutics

Clinical-stage biopharmaceutical company using structural biology and computational chemistry to ...

Montreal, Canada11–50Biotech, Drug Discovery
Grant·$360.1M·Apr 2023
Myeloid Therapeutics

Clinical-stage biotech pioneering in vivo multi-immune programming using proprietary mRNA-LNP CAR...

Cambridge, United States11–50Biotech
Series B·$356.0M·May 2026
Enveda

Biotechnology company using AI to learn from life's chemistry and discover medicines 4X faster.

Boulder, United StatesBiotech
Series C·$355.0M·Nov 2024
PIONYR ImmunotherapeuticsClosed

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenviron...

South San Francisco, United States51–200biotech, immunotherapy
Corporate Round·$355.0M·Jun 2020
ExscientiaAcquired

AI-driven drug design and development company using machine learning to create more effective med...

Oxford, United Kingdom201–500Artificial Intelligence, Biotech
Series D·$351.0M·Apr 2021
Nephron Pharmaceuticals

Pharmaceutical manufacturing and specialty drug company.

West Columbia, United States501–1000Biotech, Healthcare
Venture Unknown·$350.0M·Aug 2023
Dewpoint Therapeutics

Biotech company applying biomolecular condensate science to drug discovery across oncology, neuro...

Boston, United States51–200Life Sciences, Biotech
Series D·$346.1M·Sep 2025
Prime MedicineIPO

Biotechnology company developing one-time curative genetic therapies using Prime Editing, a preci...

Cambridge, United States201–500Biotech, Healthcare
Grant·$339.0M·Jul 2025
Aspen Neuroscience

Biotech company developing the first autologous iPSC-derived neuron replacement cell therapy for ...

San Diego, United States51–200Biotech, Healthcare
Series C·$339.0M·Nov 2025
nChroma Bio

Genetic medicines company developing targeted in vivo delivery and engineered epigenetic silencer...

Boston, United States51–200Biotech, Genomics
Corporate Round·$335.0M·Dec 2024